Corporate reporting. Find out how GSK is performing with our latest Annual Report and ESG Performance Report.

29 окт. 2024 г. · Q3 2024 sales and core earnings growth driven by strong performance of Specialty Medicines helping to offset lower Vaccines sales.

Annual Report 2023 · We are a focused biopharma company with strong momentum and big ambitions · 2023 performance and key performance indicators · Research and ...

We announced our third quarter 2024 results on Wednesday 30 October. Access our third quarter results and latest Annual Report below. Annual Report 2023 · Quarterly results · Speeches and presentations

30 окт. 2024 г. · These measures are defined and reconciliations to the nearest IFRS measure are available in the Group's Q3 2024 Results and the Group's Annual ...

This interactive publication is created with FlippingBook, a service for streaming PDFs online. No download, no waiting. Open and start reading right away!

GlaxoSmithKline plc, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines.

31 июл. 2024 г. · Broad-based performance drives sales, core profit and core EPS growth: · Total Q2 2024 sales £7.9 billion +13% · Vaccines sales +1%, +3% ex COVID.

31 июл. 2024 г. · Broad-based performance drives sales, core profit and core EPS growth: •. Total Q2 2024 sales £7.9 billion +13%.

1 мая 2024 г. · Broad-based performance drives sales, profits and earnings growth: •. Total Q1 2024 sales £7.4 billion +10% and +13% ex COVID.